Immix Biopharma (IMMX) Projected to Post Earnings on Friday

Immix Biopharma (NASDAQ:IMMX) is projected to release its earnings data before the market opens on Friday, April 4th. Analysts expect Immix Biopharma to post earnings of ($0.25) per share for the quarter.

Immix Biopharma (NASDAQ:IMMX) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.09. On average, analysts expect Immix Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immix Biopharma Stock Performance

NASDAQ IMMX opened at $1.65 on Thursday. The firm’s 50 day moving average price is $1.82 and its two-hundred day moving average price is $1.85. Immix Biopharma has a twelve month low of $1.26 and a twelve month high of $3.13. The stock has a market cap of $45.74 million, a price-to-earnings ratio of -1.94 and a beta of 0.26.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Immix Biopharma in a research report on Monday, February 10th.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.